Genetics in liver diseases

Journal of Hepatology

Volumn 46, Issue 6, 2007, Pages 1143-1148

  Pietrangelo, Antonello ^a   Oude Elferink, Ronald ^b   Prieto, Jesus ^c   Bacon, Bruce R ^d  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF NAVARRA   (Spain)

^d SAINT LOUIS UNIVERSITY   (United States)

Author keywords

Gene therapy; Genetic screening; Hereditary diseases; Polymorphisms; Quantitative trait loci

Indexed keywords

BLOOD CLOTTING FACTOR 9; INTERLEUKIN 12;

ARTICLE; CLINICAL TRIAL; DNA MICROARRAY; DOSE RESPONSE; DRUG DOSE ESCALATION; GENE MUTATION; GENE THERAPY; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC SCREENING; HEMOPHILIA B; HEREDITY; HUMAN; LIVER CELL CARCINOMA; LIVER DISEASE; PRIORITY JOURNAL; QUANTITATIVE TRAIT LOCUS;

DISEASE PROGRESSION; ENVIRONMENT; GENE THERAPY; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; LIVER; LIVER DISEASES; PHENOTYPE; POLYMORPHISM, GENETIC; QUANTITATIVE TRAIT LOCI;

EID: 34247586081     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2007.03.009     Document Type: Article

References (29)

1. Ferrari F., Foglieni B., Arosio P., Camaschella C., Daraio F., Levi S., et al. Microelectronic DNA chip for hereditary hyperferritinemia cataract syndrome, a model for large-scale analysis of disorders of iron metabolism. Hum Mutat 27 (2006) 201-208
2. Burke W. Genetic testing. N Engl J Med 347 (2002) 1867-1875
3. van Leeuwen D.J., and Bernat J.L. Ethical, social and legal implications of genetic testing in liver disease. Hepatology 43 (2006) 1195-1201
4. Abiola O., Angel J.M., Avner P., Bachmanov A.A., Belknap J.K., Bennett B., et al. The nature and identification of quantitative trait loci: a community's view. Nat Rev Genet 4 (2003) 911-916
5. Diehl A.M. Cytokine regulation of liver injury and repair. Immunol Rev 174 (2000) 160-171
6. Berasain C., Garcia-Trevijano E.R., Castillo J., Erroba E., Santamaria M., Lee D.C., et al. Novel role for amphiregulin in protection from liver injury. J Biol Chem 280 (2005) 19012-19020
7. Pauli-Magnus C., Stieger B., Meier Y., Kullak-Ublick G.A., and Meier P.J. Enterohepatic transport of bile salts and genetics of cholestasis. J Hepatol 43 (2005) 342-357
8. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 4 (2005) 489-499
9. Bataller R., North K.E., and Brenner D.A. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology 37 (2003) 493-503
10. Stickel F., and Osterreicher C.H. The role of genetic polymorphisms in alcoholic liver disease. Alcohol Alcohol 41 (2006) 209-224
11. Day C.P. The potential role of genes in nonalcoholic fatty liver disease. Clin Liver Dis 8 (2004) 673-691 xi
12. Donaldson P.T., and Czaja A.J. Genetic effects on susceptibility, clinical expression, and treatment outcome of type 1 autoimmune hepatitis. Clin Liver Dis 6 (2002) 707-725
13. Frodsham A.J., Zhang L., Dumpis U., Taib N.A., Best S., Durham A., et al. Class II cytokine receptor gene cluster is a major locus for hepatitis B persistence. Proc Natl Acad Sci USA 103 (2006) 9148-9153
14. Kato N., Ji G., Wang Y., Baba M., Hoshida Y., Otsuka M., et al. Large-scale search of single nucleotide polymorphisms for hepatocellular carcinoma susceptibility genes in patients with hepatitis C. Hepatology 42 (2005) 846-853
15. Ku N.O., Lim J.K., Krams S.M., Esquivel C.O., Keeffe E.B., Wright T.L., et al. Keratins as susceptibility genes for end-stage liver disease. Gastroenterology 129 (2005) 885-893
16. Pietrangelo A. Hereditary hemochromatosis. Annu Rev Nutr 26 (2006) 251-270
17. Panagiotakaki E., Tzetis M., Manolaki N., Loudianos G., Papatheodorou A., Manesis E., et al. Genotype-phenotype correlations for a wide spectrum of mutations in the Wilson disease gene (ATP7B). Am J Med Genet A 131 (2004) 168-173
18. Ala A., and Schilsky M.L. Wilson disease: pathophysiology, diagnosis, treatment, and screening. Clin Liver Dis 8 (2004) 787-805 viii
19. Bosma P.J. Inherited disorders of bilirubin metabolism. J Hepatol 38 (2003) 107-117
20. Thunell S., and Harper P. Porphyrins, porphyrin metabolism, porphyrias. III. Diagnosis, care and monitoring in porphyria cutanea tarda - suggestions for a handling programme. Scand J Clin Lab Invest 60 (2000) 561-579
21. Oude Elferink R.P., Paulusma C.C., and Groen A.K. Hepatocanalicular transport defects: pathophysiologic mechanisms of rare diseases. Gastroenterology 130 (2006) 908-925
22. Spirli C., Fiorotto R., Song L., Santos-Sacchi J., Okolicsanyi L., Masier S., et al. Glibenclamide stimulates fluid secretion in rodent cholangiocytes through a cystic fibrosis transmembrane conductance regulator-independent mechanism. Gastroenterology 129 (2005) 220-233
23. Wanders R.J., and Waterham H.R. Biochemistry of mammalian peroxisomes revisited. Annu Rev Biochem 75 (2006) 295-332
24. Drenth J.P., Martina J.A., van de Kerkhof R., Bonifacino J.S., and Jansen J.B. Polycystic liver disease is a disorder of cotranslational protein processing. Trends Mol Med 11 (2005) 37-42
25. Scaglia F., Brunetti-Pierri N., Kleppe S., Marini J., Carter S., Garlick P., et al. Clinical consequences of urea cycle enzyme deficiencies and potential links to arginine and nitric oxide metabolism. J Nutr 134 (2004) 2775S-2782S discussion 2796S-2797S
26. Rudnick D.A., and Perlmutter D.H. Alpha-1-antitrypsin deficiency: a new paradigm for hepatocellular carcinoma in genetic liver disease. Hepatology 42 (2005) 514-521
27. Manno C.S., Pierce G.F., Arruda V.R., Glader B., Ragni M., Rasko J.J., et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 12 (2006) 342-347
28. Wang l., Hernandez-Alcoceba R., Shankar V., Zabala M., Kochanek S., Sangro B., et al. Prolonged and inducible transgene expression in the liver using gutless adenovirus: a potential therapy for liver cancer. Gastroenterology 126 (2004) 278-289
29. Peñuelas I., Mazzolini G., Boán J.F., Sangro B., Marti{dotless}́-Climent J., Ruiz M., et al. Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients. Gastroenterology 128 (2005) 1787-1796